Significant Advancements in Lymphedema Treatment
MINNEAPOLIS, a prominent date in the field of medical technology, announces groundbreaking clinical findings from Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD). New data presented at a leading oncology meeting indicates remarkable improvements in clinical outcomes and overall quality of life for individuals suffering from lymphedema following head and neck cancer treatment.
Challenges in Current Treatment Methods
Managing lymphedema associated with head and neck cancer can be a daunting task. Traditional treatment options, including therapist-guided lymphedema therapy and self-care routines at home, often present accessibility challenges. Principal Investigator, Barbara Murphy, MD, has highlighted that these barriers prevent many patients from starting their necessary treatments promptly. As a result, Tactile Medical has developed an innovative solution that shows promise for patients seeking effective symptom management.
Flexitouch Plus as a New Therapy
Flexitouch Plus is an advanced pneumatic compression device designed specifically to enhance the treatment of lymphedema. Recent findings from a meticulous clinical trial indicate that utilizing Flexitouch Plus significantly shortens the time it takes for patients to begin effective treatment. While those relying on usual care took an average of 29.8 days to initiate treatment, patients using the APCD experienced an expedited timeline of just 17.9 days.
Study Highlights
The comprehensive clinical trial observed 236 participants across multiple sites, making it the largest of its kind for this demographic in the United States. The data collected showcased how Flexitouch Plus outperforms traditional methods in several key areas:
- Increased access: A staggering 94.9% of patients using the APCD received necessary treatment compared to only 71% in the usual care group.
- Clinical outcomes: Patients using APCD evidenced a notable decrease in swelling, surpassing the minor improvements observed in those who adhered to usual care practices.
- Quality of life benefits: Individuals using Flexitouch Plus reported substantial enhancements in their quality of life, particularly in three notable health-related metrics.
Commitment to Improving Patient Care
CEO Sheri Dodd emphasized Tactile Medical's dedication to elevating lymphedema management through substantive evidence-based advancements. With approximately 90% of head and neck cancer survivors likely to develop lymphedema, Tactile Medical's goal is to provide versatile therapies that address patients' needs. Anticipation builds as the company looks forward to revealing six-month follow-up results from this influential trial, which could support enhanced healthcare reimbursements and broaden access to vital treatment options.
About Flexitouch Plus
Flexitouch Plus is FDA-approved for at-home therapy aimed at treating lymphedema and other chronic conditions including chronic venous insufficiency (CVI). This therapy empowers patients to manage their condition effectively from the comfort of their homes.
About Tactile Systems Technology, Inc.
Tactile Medical leads the way in developing innovative, at-home therapies tailored for individuals grappling with chronic conditions such as lymphedema and chronic pulmonary diseases. Through collaborations with healthcare providers, Tactile Medical strives to enhance clinical evidence, boost awareness, and improve patient quality of life, positively influencing thousands every year.
Frequently Asked Questions
What is the Flexitouch Plus device?
Flexitouch Plus is an advanced pneumatic compression system designed to treat lymphedema effectively at home.
How does Flexitouch Plus compare to traditional treatments?
Flexitouch Plus significantly reduces the time required to initiate therapy and demonstrates superior clinical outcomes compared to traditional methods.
What clinical trial supports these findings?
The findings stem from the largest prospective, randomized controlled study focusing on head and neck cancer survivors conducted in the United States.
What percentage of patients received the necessary treatments?
In the study, 94.9% of patients using APCD received their treatments, compared to only 71% for usual care patients.
How might these findings influence healthcare reimbursement?
The trial's results are expected to advocate for improved reimbursement coverage and increased awareness among healthcare providers.
